Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Royal DSM    DSM   NL0000009827

ROYAL DSM

(DSM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Royal DSM : DSM acquires BioCare Copenhagen to expand gut health ingredients portfolio with probiotics

share with twitter share with LinkedIn share with facebook
share via e-mail
12/22/2017 | 05:39am EST

BioCare Copenhagen is a privately-held company founded in 2012, focused on probiotics and specialized in microbial actives with proven health benefits, targeting gastrointestinal disorders, metabolic disorders, infections, and immunity. The company offers high-quality white label probiotic supplements and complete product concepts with strong consumer appeal. BioCare Copenhagen has multi-market distribution agreements with a number of leading dietary supplements and pharmaceutical companies and has launched products in over 40 countries worldwide.

DSM already has a strong position in gut health solutions with its Culturelle product range, the number-one-selling probiotic dietary supplement consumer brand globally, as well as with its ingredient brands Oatwell and Tolerase. The company sees further growth potential in gut health ingredients beyond the established indications for digestive health and immune health. Fields increasingly recognized as being impacted by the gut microbiome include the gut-brain axis, metabolic health and heart health. DSM's ambition in addressing the gut microbiome and its portfolio of nutritional ingredients are very synergetic with BioCare Copenhagen's approach and products, and the combination is well-catered to address the existing and emerging gut health areas.

BioCare Copenhagen

BioCare Copenhagen is a Danish bioscience company that specializes in microbial actives targeting gastrointestinal disorders, metabolism, infections and immunity. The company's activities are based on research conducted at the Danish hospitals. BioCare Copenhagen was established as a joint venture between Borean Innovation, the Danish Ministry of Science, Technology and Innovation and the management team Søren B. Thomsen (CEO) and Jesper Gantzel (COO). For more information please see www.biocarecph.com.

Koninklijke DSM NV published this content on 22 December 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 December 2017 10:39:07 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROYAL DSM
09:20aROYAL DSM : DSM appoints new EVP Materials and member of the Executive Committee
PU
04:20aROYAL DSM : DSM - repurchase of shares (17-21 February 2020)
PU
02/21ROYAL DSM : DSM to acquire Glycom to accelerate growth in Early Life Nutrition
PU
02/18ROYAL DSM : DSM - repurchase of shares (10-14 February 2020)
PU
02/13GLOBAL MARKETS LIVE: Elon said it wouldn’t, but Tesla is once again raising b..
02/13ROYAL DSM : DSM reports 2019 results
PU
02/13ROYAL DSM : Slide show results
CO
02/13ROYAL DSM : Annual results
CO
02/11ROYAL DSM : DSM - repurchase of shares (3-7 February 2020)
PU
02/10ROYAL DSM : annual earnings release
More news
Financials (EUR)
Sales 2020 9 344 M
EBIT 2020 1 153 M
Net income 2020 841 M
Debt 2020 1 743 M
Yield 2020 2,23%
P/E ratio 2020 23,3x
P/E ratio 2021 20,7x
EV / Sales2020 2,23x
EV / Sales2021 2,08x
Capitalization 19 061 M
Chart ROYAL DSM
Duration : Period :
Royal DSM Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYAL DSM
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 117,25  €
Last Close Price 114,25  €
Spread / Highest target 28,7%
Spread / Average Target 2,63%
Spread / Lowest Target -36,1%
EPS Revisions
Managers
NameTitle
Feike Sijbesma Chairman-Management Board & CEO
Robert John Routs Chairman-Supervisory Board
Géraldine Matchett Chief Financial Officer
Pauline F. M. van der Meer Mohr Deputy Chairman
Victoria Franchetti Haynes Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
ROYAL DSM-1.59%20 689
BASF SE-12.80%58 550
SHIN-ETSU CHEMICAL CO., LTD.-0.83%51 718
DUPONT DE NEMOURS, INC.-21.42%37 302
GROUPE BRUXELLES LAMBERT-6.36%14 905
FMC CORPORATION2.58%13 273